Nova Bio-Pharma Technologies Limited

HYDRIS

Pharmaceutical and veterinary compositions, preparations and products, namely, intravenous, intramuscular, epicutaneous, intradermal, subcutaneous, oral and topical preparations, compositions and products comprising any biological and/or pharmaceutical ingredient; vaccines for human and animal use; compositions for medicinal or veterinary use comprising any biological and/or pharmaceutical ingredient; sanitary preparations for medical purposes; dietetic substances adapted for medical use; plasters, materials for dressings; filled syringes containing vaccines for medical or veterinary use;Apparatus for use in the delivery of pharmaceutical materials and drugs, namely, syringes and injectors for medical purposes; injectors and delivery devices for medical purposes containing pharmaceuticals; suture materials; with none of the above goods relating to ocular implants or delivery systems used to place the implants in the eye;Scientific and technological services; scientific research services; scientific services, technological services, scientific research services all relating to the stabilization or preservation of biological materials; industrial analysis and research services; information, advisory and consultancy services in relation to all the aforesaid services;

HYDRIS

Pharmaceutical and veterinary compositions, preparations and products in the nature of intravenous, intramuscular, epicutaneous, intradermal, subcutaneous, oral and topical preparations, compositions and products, namely, vaccine stabilizers; vaccines for human and animal use; vaccines for medicinal or veterinary use comprising biological and pharmaceutical ingredients; sanitary preparations for medical purposes; dietetic substances adapted for medical use, namely, dietetic infusions adapted for medical purposes; medical plasters and materials for medical dressings; filled syringes containing vaccines for medical or veterinary use; implantable subcutaneous drug delivery devices for medical purposes sold filled with pharmaceutical preparations for oncology and the treatment of diabetes and immunodeficiency, not relating to ocular implants or delivery systems used to place the implants in the eye;Apparatus for use in the delivery of pharmaceutical materials and drugs, namely, syringes and medical fluid injectors for medical purposes; medical fluid injectors for medical purposes; suture materials; with none of the above goods relating to ocular implants or delivery systems used to place the implants in the eye;Scientific and technological services, namely, researching and developing biomarkers for specific indications and assays in the field of the stabilization or preservation of biological materials; scientific research services for others in the field of the stabilization or preservation of biological materials; scientific services and technological services, namely, scientific research services in the field of the stabilization or preservation of biological materials; industrial analysis of immunoassays and pharmaceutical research services; scientific information, advisory and consultancy services in relation to all the aforesaid services;

LEUKOPRINE

Pharmaceutical compositions and preparations for the treatment of leukaemia; syringes sold filled with mecaptopurine; injectors and delivery devices for medical purposes containing mercaptopurine;

LIQUIPURINE

Pharmaceutical compositions and preparations for the treatment of leukaemia; syringes sold filled with mecaptopurine; injectors and delivery devices for medical purposes containing mercaptopurine;LIQUID PURINE;

NOVA

The mark consists of the wording NOVA in stylized font.;In the statement, line 6, Vaccines for human and animal use; is deleted;Line 12 through 16, scientific services in the fields of pharmaceutical, microbiological, medical and veterinary industries, namely, scientific investigations for medical purposes, scientific laboratory services; technological services in respect of pharmaceutical, microbiological, medical and veterinary preparations, namely, pharmaceutical product evaluation; scientific research services; should be deleted. Line 28 and 29, industrial analysis of pharmaceutical, microbiological, medical and veterinary preparations and research services should be deleted in class 42.;[ Vaccines for human and animal use; ] dietetic foods and/or beverages adapted for medical use;Color is not claimed as a feature of the mark.;[Apparatus for use in the delivery of pharmaceutical materials and drugs, namely, drug delivery patches sold without medication and intravenous feeding tubes; syringes and injection needles for medical purposes; suture materials];[ Scientific services in the fields of pharmaceutical, microbiological, medical and veterinary industries, namely, scientific investigations for medical purposes, scientific laboratory services; technological services in respect of pharmaceutical, microbiological, medical and veterinary preparations, namely, pharmaceutical product evaluation; scientific research services; ] process and formulation development of pharmaceutical, microbiological, medical and veterinary preparations; quality control testing of pharmaceutical, microbiological, medical and veterinary preparations; research and development regarding the optimization of the follow-up and delivery logistics for chemical products; research and development in the fields of aseptic filling and delivery devices for pharmaceutical products; vial/ampoule filling and syringe filling services; development services concerning spray drying; research and development services concerning lyophilisation; research and development services concerning emulsion manufacturing; medical device assembly services; scientific research in the field of live biologics; [ industrial analysis of pharmaceutical, microbiological, medical and veterinary preparations and research services; ] information, advisory and consultancy services in relation to all the aforesaid services;